E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10012689 |
E.1.2 | Term | Diabetic retinopathy |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The objectives of this proof-of-concept study are to investigate whether doxycycline can 1) slow the deterioration or improve retinal function and 2) induce regression, or slow progression, of diabetic retinopathy. |
|
E.2.2 | Secondary objectives of the trial | |
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Inclusion criteria include:
• age ≥ 18 years • diagnosis of type 1 or type 2 diabetes mellitus (defined as current regular use of oral anti-hyperglycemia agents and/or insulin for the treatment of diabetes) • able and willing to give informed consent • best-corrected ETDRS visual acuity in study eye ≥ 49 letters (20/100) • severe non-proliferative diabetic retinopathy (ETDRS level 53E) (19) or retinal and/or optic disk neovascularization >1/2 disc area and less than the “high-risk” characteristics defined by the Diabetic Retinopathy Study (ETDRS level 65) (17), and in whom panretinal photocoagulation is not imminently required in the ophthalmologist’s judgment • able to perform reliable visual field and dark adaptation testing • central subfield thickness on OCT of ≤ 275 m • foveal fixation present in each eye (assessed by fundus photography using an internal fixation pointer or assessed by the investigator) • media clarity and pupil dilation sufficient for high-quality fundus photographs and fluorescein angiograms.
If both eyes meet these criteria, the eye with more extensive and/or more “active” new vessels, as determined by the clinician, will be the study eye (with more active new vessel patches defined as those in which the proportion of blood-filled new vessels to fibrous tissue is greater). If both eyes have the same extent/activity of new vessels based on the clinician’s judgment, then the eye with the worse grade (as determined by the clinician) will be the study eye. If both eyes have the same grade, the eye with the better acuity will be designated the study eye, and if the acuity in both eyes is identical, the right eye will be designated the study eye.
|
|
E.4 | Principal exclusion criteria |
Ocular exclusion criteria include:
• high-risk neovascularization in study eye • prior panretinal photocoagulation in the study eye • focal/grid laser photocoagulation in the macula within the past 15 weeks in the study eye • intraocular pressure > 22mmHg by Goldmann Tonomerty • history of pars plana vitrectomy in the study eye • vitreous or pre-retinal hemorrhage in the study eye • systemic or intravitreal anti-VEGF agent to the study eye or the fellow eye within the past 3 months • peribulbar steroid injection to the study eye or the fellow eye within the past 6 months • intravitreal triamcinolone acetonide to the study eye within the past 4 months; • expectation by the investigator that retinal photocoagulation or other treatment for diabetic retinopathy (e.g. focal/grid laser to study eye, intravitreal triamcinolone acetonide to study eye, intravitreal anti-VEGF agent to study or fellow eye, ruboxistaurin or systemic anti-VEGF agent for diabetic macular edema) will be administered in the subsequent 24 months • best-corrected ETDRS visual acuity < 49 letters (20/100) in the fellow eye • an ocular condition (other than diabetes) is present in the study eye that, in the opinion of the investigator, might alter visual acuity during the course of the study (e.g. retinal vein occlusion, uveitis or other ocular inflammatory disease, neovascular glaucoma, Irvine-Gass Syndrome, etc) • anticipated need for cataract surgery in the study eye in the subsequent 24 months • history of major ocular surgery (including cataract surgery, scleral buckle, any intraocular surgery, etc) in the study eye within prior 6 months or anticipated within the subsequent 24 months following randomization • aphakia in the study eye • history of YAG capsulotomy performed in the study eye within 2 months prior to randomization.
Systemic exclusion criteria include:
• unstable medical status (e.g. glycemic control, blood pressure, cardiovascular disease) in the opinion of investigator • significant renal disease (defined as a serum creatinine > 2.5 mg/dL), • systolic blood pressure > 180 mm Hg or diastolic blood pressure > 110 mm Hg • pregnancy; for women of child-bearing potential, a urine pregnancy test will be performed. • lactating or intending to become pregnant during the study period (at least 24 months) • sexually active women of child-bearing potential not actively practicing birth control by using a medically accepted device or therapy (that is, intrauterine device, hormonal contraceptive, or barrier devices) during the study period (at least 24 months); since doxycycline may interfere with the effectiveness of hormonal contraceptives, sexually active women of child-bearing potential who use a hormonal contraceptive will be required to use a second form of contraception to safeguard against contraceptive failure while participating in the study • known allergy/intolerance to doxycycline or any ingredient in the study drug or placebo (e.g. hypromellose, iron oxide, methacrylic acid copolymer, polyethylene glycol, polysorbate 80, sugar spheres, talc, titanium dioxide, and triethyl citrate) • patients taking phenytoin, barbiturates or carbamazepine, with gastroparesis, with a history of gastrectomy, gastric bypass surgery or otherwise deemed achlorhydric or with a BMI > 30 kg/m2 will also be excluded because of altered doxycycline pharmacokinetics and/or bioavailability
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Efficacy outcome measures:
Efficacy outcomes to be assessed in this proof-of-concept study include: • change in dark adaptation (change in the duration of the rod-intercept) • change in mean deviation of scotopic full-threshold 24-2 visual fields • change in the number of abnormal points (p<5%) on the scotopic full-threshold 24-2 visual fields • change in the number of abnormal points (p<5%) in a cluster on the scotopic full-threshold 24-2 visual fields • change in mean deviation of photopic Swedish Interactive Threshold Algorithm (SITA) 24-2 visual fields • change in the number of abnormal points (p<5%) on the photopic SITA 24-2 visual fields • change in the number of abnormal points (p<5%) in a cluster on the photopic SITA 24-2 visual fields • change in foveal threshold on the photopic SITA 24-2 visual fields • change in frequency doubling perimetry (FDP) • change in ETDRS visual acuity • development of definite neovascularization in eyes free of neovascularization at baseline • increase in area of neovascularization by 50% from baseline in eyes with neovascularization at baseline • proportion of patients who receive panretinal photocoagulation during the study period • proportion of patients who develop vitreous or preretinal hemorrhage during the study period • change in total area of retinal and/or optic disk neovascularization • a >1-step progression in ETDRS diabetic retinopathy severity level • change in total area of retinal thickening • change in central subfield thickness on optical coherence tomography (OCT) • change in macular volume on OCT • proportion of patients who meet any of the following criteria: o develop definite neovascularization in eyes free of neovascularization at baseline o demonstrate an increase in area of neovascularization by 50% from baseline in eyes with neovascularization at baseline o receive panretinal photocoagulation during the study period o develop vitreous or preretinal hemorrhage during the study period • change in central retinal artery equivalent (CRAE) • change in central retinal vein equivalent (CRVE) • change in arteriovenous ratio (AVR = CRAE/CRVE)
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 5 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 5 |